Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy

Antiviral Therapy

Volumn 17, Issue 3, 2012, Pages 577-583

  Imaz, Arkaitz ^a   Olmo, Montserrat ^a   Peñaranda, Maria ^b   Gutiérrez, Félix ^c   Romeu, Joan ^d   Larrousse, Maria ^e   Domingo, Pere ^f   Oteo, José A ^g   Niubó, Jordi ^a   Curto, Jordi ^a   Vilallonga, Concepción ^b   Masiá, Mar ^c   López Aldeguer, José ^h   Iribarren, José A ⁱ   Podzamczer, Daniel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL SAN PEDRO   (Spain)

^h HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁱ HOSPITAL DONOSTIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MOLECULAR EVOLUTION; MUTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROVIRUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STRUCTURED ANTIRETROVIRAL THERAPY INTERRUPTION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84861664052     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2025     Document Type: Article

References (21)

1. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
2. Kaufmann GR, Elzi L, Weber R, et al. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS 2011; 25:441-451.
3. Fox Z, Phillips A, Cohen C, et al. Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitorbased regimen. AIDS 2008; 22:2279-2289.
4. Hare CB, Mellors J, Krambrink A, et al. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 2008; 47:421-424. (Pubitemid 352009367)
5. Martinez-Picado J, Morales-Lopetegi K, Wrin T, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002; 16:895-899. (Pubitemid 34409013)
6. Arnedo-Valero M, Garcia F, Gil C, et al. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Infect Dis 2005; 41:883-890. (Pubitemid 41266758)
7. Olmo M, Podzamczer D, Peñaranda M, et al. A randomized trial of CD4-guided HAART interruption in patients receiving mostly NNRTI-based regimens: 96 week results. 11th European AIDS Conference/EACS. 24-27 October 2007, Madrid, Spain. Abstract P7.6/02
8. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS 2002; 16:605-613. (Pubitemid 34218856)
9. Niubò J, Li W, Henry K, Erice A. Recovery and analysis of human immunodeficiency virus type 1 (HIV) RNA sequences from plasma samples with low HIV RNA levels. J Clin Microbiol 2000; 38:309-312. (Pubitemid 30043307)
10. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156-163
11. Nuesch R, Ananworanich J, Sirivichayakul S, et al. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis 2005; 40:728-734. (Pubitemid 40381349)
12. Cressey TR, Green H, Khoo S, et al. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin Infect Dis 2008; 46:1601-1608. (Pubitemid 351706744)
13. Pirillo M, Palmisano L, Pellegrini M, et al. Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial. AIDS Res Hum Retroviruses 2010; 26:541-545.
14. Boucher S, Recordon-Pinson P, Neau D, et al. Clonal analysis of HIV-1 variants in proviral DNA during treatment interruption in patients with multiple therapy failures. J Clin Virol 2005; 34:288-294. (Pubitemid 41605445)
15. Paolucci S, Baldanti F, Campanini G, et al. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J Med Virol 2001; 65:207-217. (Pubitemid 32816689)
16. Wang YM, Dyer WB, Workman C, et al. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and noninterrupted HAART. Curr HIV Res 2007; 5:235-250. (Pubitemid 46488199)
17. Saracino A, Gianotti N, Marangi M, et al. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. J Med Virol 2008; 80:1695-1706.
18. Bi X, Gatanaga H, Ida S, et al. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr 2003; 34:1-6. (Pubitemid 37100105)
19. Palmisano L, Giuliano M, Galluzzo CM, et al. The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy. HIV Med 2009; 10:477-481.
20. Bi X, Gatanaga H, Koike K, Kimura S, Oka S. Reversal periods and patterns from drug-resistant to wild-type HIV type 1 after cessation of anti-HIV therapy. AIDS Res Hum Retroviruses 2007; 23:43-50. (Pubitemid 46214170)
21. Wirden M, Soulie C, Valantin MA, et al. Historical HIVRNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. J Antimicrob Chemother 2011; 66:709-712.